The N-end rule relates the metabolic stability of a protein to the identity of its amino-terminal residue.
At least some proteins are short-lived in vivo because they contain sequences (degradation signals) that make these proteins substrates of specific proteolytic pathways. An essential component ofone degradation signal is the protein's amino-terminal residue (1) . This degradation signal is manifested as the N-end rule, which relates the metabolic stability of a protein to the identity of its amino-terminal residue (1) (2) (3) (4) (5) (6) (7) (8) . Similar but distinct versions of the N-end rule operate in mammals (2, 5, (8) (9) (10) (11) , yeast (1-5, 7, 12) , and bacteria (J. Tobias and A.V., unpublished results).
The N-end rule-based degradation signal in eukaryotes comprises a destabilizing amino-terminal residue and a specific internal lysine residue (1) (2) (3) (4) (5) 8) . The set of destabilizing amino-terminal residues is organized hierarchically. Specifically, amino-terminal Asp and Glu (and Cys in mammalian reticulocytes) are secondary destabilizing residues in that they are destabilizing through their ability to be conjugated to Arg, aprimary destabilizing residue (1, (5) (6) (7) . Amino-terminal Asn and Gln are tertiary destabilizing residues in that they are destabilizing through their ability to be converted, via selective deamidation, into the secondary destabilizing residues Asp and Glu (5) .
Previous work (1) has predicted the existence of "N-endrecognizing" proteins that select potential proteolytic substrates by binding to their amino-terminal residues. N-endrecognizing proteins have recently been detected in an in vitro ubiquitin-dependent proteolytic system derived from mammalian reticulocytes, and identified as the E3 proteins that were previously shown to bind proteolytic substrates prior to their ubiquitination by a subset of ubiquitinconjugating (E2) enzymes (5, 9, 10, 12, 13) . Three distinct types of E3 activity have been detected in the reticulocytederived in vitro system by using assays based on selective inhibition of the degradation of specific proteins by dipeptides bearing different destabilizing amino-terminal residues. The type I E3 activity is specific for the positively charged destabilizing amino-terminal residues Arg, Lys, and His (5, 9) . The type II activity is specific for the bulky hydrophobic destabilizing amino-terminal residues Phe, Trp, Tyr, and Leu (and lie in yeast) (5, 9) . The type III activity is specific for the amino-terminal residues Ala, Ser, and Thr, which share the properties of small size and lack of charge (5). Ala, Ser, and Thr are destabilizing in reticulocytes but stabilizing in yeast, implying that Saccharomyces cerevisiae lacks type III E3 activity (1, 5) .
The efficient and selective inhibition of the N-end rule pathway by amino acid derivatives in reticulocyte extract has prompted us to ask, using S. cerevisiae as a model system, whether a similar approach is feasible with intact cells. The ability to perturb the N-end rule pathway in vivo would provide a powerful tool for studies of this pathway, especially in organisms where genetic analysis is difficult, and might also prove useful in pharmacological and biotechnological applications. We show that the in vivo inhibition of the N-end rule pathway with amino acid derivatives is feasible and should be generally applicable. We next asked whether amino acid derivatives, once taken up by the cell, could inhibit the N-end rule pathway in vivo. The model substrates used were derivatives of Escherichia coli 8gal. In eukaryotes, Ub-X-/3gal fusion proteins are precisely deubiquitinated either in vivo or in cell-free extracts by an endogenous Ub-specific processing protease to yield X-,Bgal proteins bearing the residue X at the amino terminus (1, 5) . Depending on the identity ofX, the X-/3gal proteins are either long-lived or metabolically unstable, with destabilizing amino-terminal residues conferring short half-lives on the corresponding X-fBgal proteins (1) (2) (3) (4) (5) (6) (7) (8) .
METHODS
In preliminary experiments, yeast expressing various Ub-X-fBgal proteins were plated on SD-galactose medium containing amino acid derivatives and the chromogenic fgal substrate 5-bromo-4-chloro-3-indolyl B-D-galactoside (see Methods and ref. 14). The results (not shown) were consistent with the possibility, to be confirmed below, that certain amino acid derivatives (but not equimolar amounts of their constituent free amino acids) could increase steady-state levels of normally short-lived X-fBgal proteins. These effects were quantified by measuring the enzymatic activity of intracellular X-pgal proteins as a function of either the intracellular concentration of an amino acid derivative or the elapsed incubation time. An initial experiment ( The maximal effect of Leu-OMe (after 1 hr of incubation)
on the levels of X-,Bgal proteins with type II (bulky hydrophobic) destabilizing amino-terminal residues (5, 9) was reached at -10 mM Leu-OMe (Fig. 1B) A to OD6w of -0.5, followed by the addition of either Arg-Ala (to 10 mM; e), Ala-Arg (to 10 mM; o) or peptide-free buffer (see Methods) (o), and further growth for 8 hr. Cells from half the culture containing Arg-Ala were collected by centrifugation, washed, resuspended, and grown further in SD-galactose lacking Arg-Ala (v).
in cells was -70-fold higher than that in cells from a parallel culture grown in the absence of Leu-OMe (Fig. 1C) . The rate of increase in the level of Leu-fBgal became progressively slower after 8 hr in the presence of Leu-OMe (data not shown).
The amount of Arg-fBgal in cells increased -55-fold over its normal steady-state level after 8 hr of incubation with ArgAla dipeptide at 10 mM (Fig. 1D) . Crucially, Ala-Arg, a dipeptide of the same composition as Arg-Ala but with a stabilizing amino-terminal residue, had no effect on the in vivo level of Arg-,Bgal (Fig. 1D ), in agreement with the earlier observations in reticulocyte extract (5, 9) that the identity of the amino-terminal residue in a dipeptide determines its specificity and activity in the inhibition of the N-end rule pathway. [That Ala-Arg had actually been taken up by cells was indicated by its ability to support the growth of an arginine auxotroph (data not shown).] The in vivo inhibition of X-3gal degradation by amino acid derivatives was completely reversible: removal of an inhibitor from the medium 
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Leu-OMe (mM) Fig. 1 C and D) . (Fig. 2) . The Trp-Ala dipeptide, similarly to LeuOMe (Fig. 1B) , metabolically stabilized Leu-, Phe-, Trp-, Tyr-, and Ile-Pgal but did not have an effect on any other X-f3gal tested, including Arg-, Lys-, and His-fgal (Fig. 2) . No X-f3gal proteins were stabilized by the Ala-Trp dipeptide (Fig.   2 ). These results provided in vivo evidence for the existence of type I and type II primary destabilizing residues, a feature of the N-end rule pathway originally defined in reticulocyte extract (5, 9 The recent cloning of the gene (UBRI) for an N-endrecognizing (E3) protein of S. cerevisiae has made possible in vitro tests of the recognition specificity of this 225-kDa protein (12) . UBR1 specifically binds in vitro to proteins bearing either type I or type II primary destabilizing aminoterminal residues but does not bind to otherwise identical proteins bearing stabilizing amino-terminal residues (12). Similar conclusions have been reached from the analysis of the partially purified counterpart of UBR1 from rabbit reticulocytes (18) . Since the type I and type II binding activities 500 rcan be inhibited independently in the yeast UBR1 in vivo (Fig. 2) and in a mammalian counterpart of UBR1 in vitro (5, 9, 18) , it is likely that the corresponding binding sites are distinct in both of these proteins.
The Arg-Ala dipeptide, while increasing the levels of X-Pgal proteins bearing type I (basic) destabilizing aminoterminal residues (Fig. 2) , decreased the levels of X-fSgal proteins bearing type II (bulky hydrophobic) destabilizing amino-terminal residues. For instance, after 3 hr in the presence of Arg-Ala, the levels of Tyr-,8gal and Leu-f8gal
were decreased, respectively, to =80% and =30%o of their levels in the absence of the dipeptide (Fig. 2 and data not shown). The "converse" effect was not observed, however: Trp-Ala, while increasing the levels of X-f3gal proteins bearing type II destabilizing residues, did not affect the levels of X-,Bgal proteins bearing type I destabilizing residues (Fig. 2) . In addition to stabilizing Arg-, Lys-, and His-f3gal, the Arg-Ala (but not Ala-Arg) dipeptide metabolically stabilized Asp-pgal and Asn-f3gal, which bear, respectively, a secondary and a tertiary destabilizing amino-terminal residue ( Fig.  2 ; see Introduction for terminology). This result provided an in vivo confirmation of the hierarchical organization of the N-end rule, in which a secondary (and after deamidation, a tertiary) destabilizing residue is conjugated, via Arg-tRNAprotein transferase, to arginine, a type I primary destabilizing residue (5-7).
Independent in vivo confirmation of these aspects of the N-end rule was provided by the recent cloning of the S. cerevisiae genes ATE) and DEAl, which encode, respectively, Arg-tRNA-protein transferase (7) and a deamidase specific for amino-terminal Asn and Gln (unpublished results). As expected from the hierarchical structure of the N-end rule (5), null deal mutants are unable to degrade substrates that start with tertiary destabilizing residues (Asn or Gln), whereas null ate] mutants are unable to degrade substrates that start with either tertiary (Asn or Gln) or secondary (Asp or Glu) destabilizing residues (ref. 7 and unpublished data).
Recently, Kopitz et al. (19) reported that a short-lived enzyme, ornithine decarboxylase, could be arginylated in extracts from rat hepatocytes by an endogenous Arg-tRNAprotein transferase, and furthermore, that the in vivo degradation of ornithine decarboxylase in hepatocytes could be partially suppressed by the tripeptide Glu-Val-Phe, a substrate of Arg-tRNA-protein transferase. While still indirect, these results suggest that ornithine decarboxylase is a substrate of the N-end rule pathway that bears a secondary or a tertiary destabilizing amino-terminal residue. If so, it should now be possible to use amino acid derivatives to inhibit, in vivo, both the amino-terminal modification of such proteins and their subsequent recognition by E3.
One parameter that is expected to determine the effectiveness of an amino acid derivative as an in vivo inhibitor of the N-end rule pathway is the derivative's metabolic stability. To see whether making a dipeptide more resistant to proteolytic cleavage would augment its inhibitory effect, we tested the dipeptide L-Arg-D-Ala, whose second residue is a D-stereoisomer, and found that this dipeptide was more effective in raising steady-state levels of the relevant short-lived X-/3gal proteins than was the Arg-Ala dipeptide in which both residues are L-stereoisomers (Fig. 2) . Whether the greater effectiveness of L-Arg-D-Ala is due to its (expected) longer half-life in vivo or to other reasons, such as higher rate of uptake, remains to be determined.
Metabolic Stabilization of X-,tgal Proteins in Vivo. Pulsechase analysis was used to follow the degradation of newly formed X-,Bgal proteins in the presence or absence of amino acid derivatives (Figs. 3 and 4) . As noted previously (1, 3) , the in vivo degradation ofX-,3gal proteins did not obey first-order kinetics but instead slowed with time. More precisely, the kinetics of degradation deviated from first order when sufficiently long chase periods (>10 min at 30°C) were used (Fig.  4A) . For chases shorter than 10 min (with 1-min pulses), the degradation kinetics were close to first order for all of the short-lived X-,Bgal proteins tested (Fig. 4 B and C; 10 and 30, respectively) , extraction, immunoprecipitation, and electrophoretic analysis of X-pgal (see Methods). Where indicated, a 60-min (lanes 60) chase point was also taken. In the experiments where amino acid derivatives were present (at 10 mM) during growth, labeling, and chase, their names are shown above the lanes. Identities of X-/3gal proteins are indicated at left. Arrowhead denotes an "90-kDa long-lived 8gal cleavage product specific for short-lived X-jBgal proteins (1, 4) . Filled circle (at right) denotes an -95-kDa long-lived ,gal cleavage product specific for long-lived X-,fgal proteins (4). Asterisk denotes an unknown S. cerevisiae protein that crossreacts with the monoclonal antibody to 8gal (1).
absence of the Arg-Ala dipeptide and =20 min in its presence (Fig. 4C). [Northern hybridization analyses (data not shown) indicated that the addition of amino acid derivatives did not change the levels of mRNAs encoding the corresponding X-,3gal proteins.] Pulse--chase analysis also detected two further changes that have previously been shown to accompany metabolic stabilization of X-jBgal proteins: the diminished accumulation of an -90-kDa ,Bgal cleavage product specific for short-lived X-,gal species (1, 4) , and the appearance of an -95-kDa 8Bgal cleavage product specific for long-lived X-f3gal species (4) (Fig. 3) .
Another effect of the amino acid derivatives was an increase in the amount of 35S in the pulse-labeled X-fPgal species (a "zero-time" increase) that was especially pronounced for the shorter-lived proteins such as Leu-and Arg-l3gal (Fig. 3 and Fig. 4 B and C) . The zero-time increase was expected because metabolic stabilization ofa protein will result in its greater net incorporation of label during a pulse of constant duration, since a smaller fraction of the stabilized protein is degraded during this time.
We do not understand the reasons for non-first-order kinetics of X-fgal degradation in yeast (Fig. 4A, refs. 1 (20) . Among potential explanations of the non-exponential X-flgal degradation is a hypothesis that the assembly and "maturation" of an X-fgal tetramer make it progressively more resistant to targeting and/or degradation by the N-end rule pathway. Another possible explanation is that an essential targeting component of the N-end rule pathway has affinity for ribosomes, so that a newly formed substrate of the N-end rule pathway, being in the immediate vicinity of a ribosome, has a greater chance of being targeted for degradation than the same substrate at later times and farther away from the sites of translation. Irrespective of its specific explanations, the non-first-order kinetics of X-p8gal degradation makes it possible to account for the apparent discrepancy between, for instance, an -10-fold metabolic stabilization of Leu-fpgal by Leu-OMe in the 1-min pulse/10-min chase assay (Fig. 4B) , and an n70-fold increase in the level of the same Leu-/3gal after 8 hr of incubation with Leu-OMe (Fig. 1C) . Indeed, since the in vivo degradation of an X-jSgal slows with time (Fig. 4A) , a partial metabolic stabilization by an amino acid derivative of more recently formed (and hence shorter-lived) X-jBgal molecules would increase the steady-state level of an X-Pgal to a greater extent than the same degree of metabolic stabilization of "older" (and hence longer-lived) X-j8gal molecules. This argument accounts for the relative increase of an "early" half-life of an X-f3gal (Fig. 4 B and C) being lower than the relative increase of its steady-state level in the presence of an amino acid derivative ( Fig. 1 C and D) . (For a first-order decay in the absence of changes in the rate of protein synthesis, the relative increase of a protein's half-life equals the relative increase in its maximal steady-state concentration.)
The ability to inhibit the N-end rule pathway in vivo may have practical applications and, in addition, provides a powerful tool for studies of this pathway.
